Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON ‐HF trial

ConclusionsIn real-world HFpEF (LVEF  ≥ 45%) with N-terminal pro-B-type natriuretic peptide and cardiac structure/function assessed, eligibility for sacubitril/valsartan was according to PARAGON-HF complete criteria 34%, pragmatic criteria 63%, LVEF below lower limit of normal range 5.4%, and LVEF below mean of normal range 41%. Ca rdiac structural impairment was almost ubiquitous. Ineligibility was more due to exclusion criteria than failing to meet inclusion criteria.

Source: ESC Heart Failure - November 23, 2021 Category: Cardiology Authors: Lars H. Lund, Gianluigi Savarese, Ashwin Venkateshvaran, Lina Benson, Anna Lundberg, Erwan Donal, Jean ‐Claude Daubert, Emmanuel Oger, Cecilia Linde, Camilla Hage Tags: Original Article Source Type: research